SG11201405803PA - Vaccine against rsv - Google Patents

Vaccine against rsv

Info

Publication number
SG11201405803PA
SG11201405803PA SG11201405803PA SG11201405803PA SG11201405803PA SG 11201405803P A SG11201405803P A SG 11201405803PA SG 11201405803P A SG11201405803P A SG 11201405803PA SG 11201405803P A SG11201405803P A SG 11201405803PA SG 11201405803P A SG11201405803P A SG 11201405803PA
Authority
SG
Singapore
Prior art keywords
vaccine against
against rsv
rsv
vaccine
Prior art date
Application number
SG11201405803PA
Other languages
English (en)
Inventor
Katarina Radosevic
Jerôme H H V Custers
Jort Vellinga
Myra N Widjojoatmodjo
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of SG11201405803PA publication Critical patent/SG11201405803PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201405803PA 2012-03-22 2013-03-21 Vaccine against rsv SG11201405803PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614429P 2012-03-22 2012-03-22
EP12160682 2012-03-22
PCT/EP2013/055935 WO2013139911A1 (en) 2012-03-22 2013-03-21 Vaccine against rsv

Publications (1)

Publication Number Publication Date
SG11201405803PA true SG11201405803PA (en) 2014-11-27

Family

ID=49221877

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201405804YA SG11201405804YA (en) 2012-03-22 2013-03-21 Vaccine against rsv
SG11201405803PA SG11201405803PA (en) 2012-03-22 2013-03-21 Vaccine against rsv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201405804YA SG11201405804YA (en) 2012-03-22 2013-03-21 Vaccine against rsv

Country Status (15)

Country Link
EP (2) EP2827894B1 (ja)
JP (2) JP5805908B2 (ja)
KR (2) KR102050616B1 (ja)
CN (2) CN104334188B (ja)
AP (2) AP2014007994A0 (ja)
AR (2) AR090470A1 (ja)
AU (2) AU2013237424B2 (ja)
BR (1) BR112014023196B1 (ja)
CA (2) CA2867955C (ja)
EA (2) EA026620B1 (ja)
MY (2) MY169331A (ja)
NZ (2) NZ630753A (ja)
SG (2) SG11201405804YA (ja)
TW (2) TWI624545B (ja)
WO (2) WO2013139916A1 (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2869841T1 (sl) 2012-07-05 2022-02-28 Glaxosmithkline Biologicals Sa Novi režimi za ojačitev odziva, ki vključujejo imunogene polipeptide, ki jih kodirajo polinukleotidi
RU2015146762A (ru) * 2013-04-08 2017-05-16 МЕДИММЬЮН, ЭлЭлСи Композиция вакцины и способ применения
ES2715378T3 (es) 2013-04-25 2019-06-04 Janssen Vaccines & Prevention Bv Polipéptidos F de prefusión del virus sincicial respiratorio (RSV) solubles y estabilizados
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
US10100372B2 (en) 2014-06-18 2018-10-16 Georgia State University Research Foundation, Inc. Recombinant RSV reporter virus
WO2016144675A1 (en) * 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
CA2981841A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
MX2017016101A (es) * 2015-06-12 2018-02-21 Glaxosmithkline Biologicals Sa Polinucleotidos y polipetidos de adenovirus.
EA035909B1 (ru) 2015-07-07 2020-08-31 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
CN116063551A (zh) 2016-04-05 2023-05-05 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f蛋白
EP3439694A1 (en) * 2016-04-05 2019-02-13 Janssen Vaccines & Prevention B.V. Vaccine against rsv
WO2017194655A1 (en) 2016-05-12 2017-11-16 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
JP2019523644A (ja) 2016-05-30 2019-08-29 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された融合前ｒｓｖ ｆタンパク質
AU2017283118B2 (en) 2016-06-20 2019-02-07 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
EA202090738A1 (ru) * 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
MX2021013947A (es) * 2019-05-15 2021-12-14 Janssen Vaccines & Prevention Bv Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.
CA3140230A1 (en) * 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
JP2023525114A (ja) 2020-05-12 2023-06-14 ヤンセン ファッシンズ アンド プリベンション ベーフェー 同種アデノウイルスベクターの投与
RU2731356C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
RU2731342C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
MX2022002609A (es) * 2020-08-22 2022-06-08 Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte Vector de expresion para el desarrollo de un agente inmunobiologico para inducir inmunidad especifica contra el virus de sindrome respiratorio agudo grave sars-cov-2 (variantes).
EP4003414A4 (en) * 2020-08-22 2023-05-10 Fed. State Budgetary Institution "Nat. Res. Centre for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya" of the .... MEDICATIONS TO INDUCE SPECIFIC IMMUNITY AGAINST SARS-COV-2
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
WO2022215436A1 (ja) * 2021-04-05 2022-10-13 株式会社クボタ 管理機制御システム
WO2023217189A2 (zh) * 2022-05-10 2023-11-16 康希诺生物股份公司 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用
CN116003536A (zh) * 2022-09-23 2023-04-25 暨南大学 呼吸道合胞病毒融合前f蛋白突变体及其应用
WO2024093554A1 (zh) * 2022-11-04 2024-05-10 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
KR20050043996A (ko) 1996-07-01 2005-05-11 아방티 파르마 소시에테 아노님 재조합 아데노바이러스의 제조방법
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
AU732703B2 (en) 1996-11-20 2001-04-26 Crucell Holland B.V. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
EP0973866A4 (en) 1997-03-04 2000-04-19 Baxter Int ADENOVIRUS E1-COMPLEMENTING CELL LINES
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
BR9908015A (pt) 1998-02-17 2001-04-24 Schering Corp Composições que compreendem vìrus e métodos para concentração de preparações de vìrus
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
CA2350890C (en) 1998-11-16 2014-07-08 Introgen Therapeutics, Inc. Aqueous compositions for long-term stable storage of adenovirus particles including uses and methods for preparing same
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ATE519855T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus des serotyps ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
EP1453537A1 (en) 2001-12-12 2004-09-08 FH Faulding & Co. Limited Composition for viral preservation
EP1465664A1 (en) 2002-01-18 2004-10-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
PL208588B1 (pl) 2002-04-25 2011-05-31 Crucell Holland Bv Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa
DE60335672D1 (de) 2002-05-14 2011-02-17 Merck Sharp & Dohme Verfahren zur reinigung von adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
SI1670925T1 (sl) * 2003-10-02 2013-10-30 Crucell Holland B.V. Pakirne celice za rekombinantni adenovirus
CN101343625A (zh) 2004-02-23 2009-01-14 克鲁塞尔荷兰公司 病毒纯化方法
BRPI0510475B8 (pt) * 2004-05-26 2021-05-25 Bayer Pharma AG adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
ES2358523T3 (es) * 2004-10-13 2011-05-11 Crucell Holland B.V. Vectores adenovirales mejorados y usos de los mismos.
US20080254059A1 (en) * 2005-02-11 2008-10-16 Bett Andrew J Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby
DE602006003420D1 (de) 2005-04-11 2008-12-11 Crucell Holland Bv Virusreinigung mit ultrafiltration
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
CN101012463A (zh) * 2007-01-19 2007-08-08 安徽医科大学 HDAd/F载体及制备方法和用途
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
KR101504392B1 (ko) 2008-11-03 2015-03-19 크루셀 홀란드 비.브이. 아데노바이러스 벡터의 제조방법
US9095546B2 (en) 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
JP5465331B2 (ja) 2009-10-15 2014-04-09 クルセル ホランド ベー ヴェー 高細胞密度の培養物からのアデノウイルスの精製方法
CA2776461C (en) 2009-10-15 2020-08-25 Crucell Holland B.V. Method for the purification of adenovirus particles.
WO2011056899A2 (en) * 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN102762721B (zh) 2010-02-15 2015-03-11 克鲁塞尔荷兰公司 用于生产Ad26腺病毒载体的方法
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine

Also Published As

Publication number Publication date
TWI624545B (zh) 2018-05-21
KR20140138765A (ko) 2014-12-04
EA026620B1 (ru) 2017-04-28
WO2013139916A1 (en) 2013-09-26
CN105431169A (zh) 2016-03-23
AR090469A1 (es) 2014-11-12
AU2013237429B2 (en) 2015-07-23
BR112014023196B1 (pt) 2021-09-08
EP2827894A1 (en) 2015-01-28
EP2827895A1 (en) 2015-01-28
AU2013237424A1 (en) 2014-10-16
JP2015512380A (ja) 2015-04-27
NZ630753A (en) 2016-12-23
AR090470A1 (es) 2014-11-12
CN105431169B (zh) 2019-04-02
WO2013139911A1 (en) 2013-09-26
EP2827895B1 (en) 2017-08-09
BR112014023196A2 (ja) 2017-06-20
TWI640534B (zh) 2018-11-11
JP5805908B2 (ja) 2015-11-10
CA2867955A1 (en) 2013-09-26
SG11201405804YA (en) 2014-10-30
AU2013237424B2 (en) 2017-07-06
AP2014007993A0 (en) 2014-10-31
CA2867955C (en) 2023-02-07
EP2827894B1 (en) 2017-05-17
AP2014007994A0 (en) 2014-10-31
JP5845376B2 (ja) 2016-01-20
TW201343669A (zh) 2013-11-01
EA026504B1 (ru) 2017-04-28
CN104334188B (zh) 2016-08-24
EA201491754A1 (ru) 2014-12-30
JP2015519295A (ja) 2015-07-09
AU2013237429A1 (en) 2014-10-09
EA201491752A1 (ru) 2015-02-27
MY169331A (en) 2019-03-21
CA2867950C (en) 2023-02-21
TW201341531A (zh) 2013-10-16
KR102050616B1 (ko) 2019-12-03
CN104334188A (zh) 2015-02-04
CA2867950A1 (en) 2013-09-26
MY169352A (en) 2019-03-25
NZ630649A (en) 2016-12-23
KR102023791B1 (ko) 2019-09-23
KR20140138769A (ko) 2014-12-04

Similar Documents

Publication Publication Date Title
AP2014007994A0 (en) Vaccine against rsv
HK1207967A1 (en) Vaccine
EP2916795A4 (en) IMPROVED ROLLATOR
GB201304182D0 (en) No details
GB201403961D0 (en) No details
EP2876161A4 (en) VACCINE
GB201223386D0 (en) Vaccine
IL231043A0 (en) vaccine
GB201411220D0 (en) No details
IL234604A (en) Carbon-glycophide vaccines are vaccinated
GB201119999D0 (en) Vaccine
EP2763699A4 (en) VACCINE
GB201205237D0 (en) Adjuvant
EP2822599A4 (en) VACCINE
GB201313844D0 (en) No details
ZA201500149B (en) Slip
GB201202090D0 (en) Vaccine
GB201403415D0 (en) No details
GB201120000D0 (en) Vaccine
HK1206272A1 (en) Vaccine against rsv rsv
DK2846829T3 (en) Vaccine combinations
GB201217321D0 (en) Vaccine
GB201210226D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201205599D0 (en) Vaccine